Jorge Castellanos, MD
Pulmonary Disease · Hialeah, FLNPI 1326077967
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,746 of the $7,845 with a category attached, or 60.5%. 15 manufacturers reported payments, led by Edwards Lifesciences at 45.3% of the total. 2025 is the largest year on record at $2,951, 2.9 times the $1,015 reported in 2019.
Across 173 payments — averaging $45.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- GSK$2K
- AstraZeneca$1K
- Sanofi$256
- Abbott$241
- Mallinckrodt Hospital Products Inc.$217
- plus $551 from 9 others
Across 1 payment — averaging $16,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$16K
What the payments were for
- Travel & lodging$3,09939%
- Food & beverage$4,74661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 15 | $3,554 |
| GSK | 57 | $1,555 |
| AstraZeneca | 63 | $1,470 |
| Sanofi | 7 | $256 |
| Abbott | 6 | $241 |
| Mallinckrodt Hospital Products Inc. | 7 | $217 |
| Boehringer Ingelheim | 7 | $163 |
| Shockwave Medical, Inc | 1 | $159 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Boston Scientific | 1 | $40 |
| Mylan Specialty L.p. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Cathworks, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,845 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 544 | $352,343 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 416 | $280,117 |
| SymbicortBudesonide/Formoterol Fumarate | 343 | $86,209 |
| Breo ElliptaFluticasone/Vilanterol | 187 | $81,764 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 63 | $37,025 |
| Spiriva RespimatTiotropium Bromide | 46 | $23,504 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $18,816 |
| Spiriva HandihalerTiotropium Bromide | 37 | $18,719 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 939 | $18,297 |
| Atrovent HfaIpratropium Bromide | 25 | $11,643 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 133 | $11,033 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 80 | $9,805 |
| Wixela InhubFluticasone Propion/Salmeterol | 152 | $8,982 |
| BreynaBudesonide/Formoterol Fumarate | 88 | $8,193 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $7,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $1,470 | $438,552887 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,555 | $380,697635 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $163 | $68,447126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Hialeah
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.